Peginterferon Lambda-1a/ribavirin with daclatasvir or peginterferon alfa-2a/ribavirin with telaprevir for chronic hepatitis c genotype 1b

Journal of Interferon and Cytokine Research

Volumn 36, Issue 11, 2016, Pages 635-643

  Flisiak, Robert ^a   Kawazoe, Seiji ^b   Znoyko, Olga ^c   Assy, Nimer ^d   Gadano, Adrian ^e   Kao, Jia Horng ^f   Lee, Kwan Sik ^g   Zwirtes, Ricardo ^h   Portsmouth, Simon ^h   Dong, Yuping ^h   Xu, Dong ^h   Kumada, Hiromitsu ⁱ   Srinivasan, Subasree ^h  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Saga Prefectural Hospital Koseikan   (Japan)

^c A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^d Rebecca Sieff Government Hospital   (Israel)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g Yonsei University College of Medicine   (South Korea)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ TORANOMON HOSPITAL   (Japan)

Author keywords

Clinical trial; Daclatasvir; Hepatitis c; Interferon lambda 1a; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DACLATASVIR; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CHILL; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HUMAN; JAUNDICE; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MYALGIA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; YOUNG ADULT;

EID: 84994591741     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0173     Document Type: Article

References (31)

1. AASLD/IDSA/IAS-USA. 2015. Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis Cvirus.Hepatology 62(3): 932-954.
2. Aghemo A, De Francesco R. 2015. Daclatasvir: A team player rather than a prima donna in the treatment of hepatitis C. Gut 64(6):860-862.
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207-1217.
4. Bunchorntavakul C, Reddy KR. 2015. Review article: The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 42(3):258-272.
5. Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Moreno C, Streinu-Cercel A, Verheyen A, Iraqi W, DeMasi R, Hill A, Lauffer JM, Lonjon- Domanec I, Wedemeyer H. 2014. Safety and on-Treatment efficacy of telaprevir: The early access programme for patients with advanced hepatitis C. Gut 63(7):1150-1158.
6. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4):896-906.
7. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279(31):32269-32274.
8. European Association for the Study of the Liver. 2015. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63(1):199-236.
9. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. 2014. Efficacy of an interferonand ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146(2):420-429.
10. Herbst DA, Reddy KR. 2013. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 22(10):1337-1346.
11. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourliere M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Brau N, Hernandez D, McPhee F, Wind- Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. 2015. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: A randomised study. Gut 64(6):948-956.
12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405-2416.
13. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
14. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. 2014. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59(6):2083-2091.
15. Lauer GM, Walker BD. 2001. Hepatitis C virus infection. N Engl J Med 345(1):41-52.
16. Liu J, Jadhav PR, Amur S, Fleischer R, Hammerstrom T, Lewis L, Naeger L, O'Rear J, Pacanowski M, Robertson S, Seo S, Soon G, Birnkrant D. 2013. Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naive and experienced subjects. Hepatology 57(3):897-902.
17. LokAS, Gardiner DF, HezodeC, Lawitz EJ, BourliereM, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-RotoloM, Yu F, McPhee F, GraselaDM, Pasquinelli C. 2014. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 60(3):490-499.
18. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366(3):216-224.
19. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. 2014. Alloral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study. Lancet 384(9954):1597-1605.
20. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77-87.
21. Muir A, Gong L, Johnson LSG, Lee MTM, Williams MS, Klein TE, Caudle KE, Nelson DR. 2014a. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-A-based regimens. Clin Pharmacol Ther 95(2):141-146.
22. Muir A, Jurkowski C, Cooney E, Hillson J, Lataillade M. 2013. Safety profile of peginterferon lambda for treatment of chronic hepatitis B (CHB) or chronic hepatitis C (CHC): cross-study analysis of patients treated in three phase 2 studies. 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting. Washington, DC, November 1-5, 2013. Abstract 1103.
23. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. 2014b. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol 61(6):1238-1246.
24. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hezode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. 2015. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 313(17): 1736- 1744.
25. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hezode C, Lim JK, Bronowicki JP, Abrams GA, Brau N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. 2012. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: A randomised, parallel-group, double-blind, placebo-controlled, dosefinding, phase 2a trial. Lancet Infect Dis 12(9):671-677.
26. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195-1206.
27. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Brau N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Ledinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD, UNITY-1 Study Group. 2015. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 313(17):1728-1735.
28. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL- 28R. Nat Immunol 4(1):63-68.
29. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. 2014. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370(3): 211-221.
30. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. 2011. Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417-2428.
31. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFNlike response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-Activated protein kinases. J Virol 81(14):7749-7758.